ClinicalTrials.gg
RecruitingNCT05180786Updated Oct 24, 2024

Error-enhanced Learning & Recovery in 2 & 3 Dimensions

An interventional study of Error Fields and No Error Fields in Stroke and Cerebral Vascular Accident (CVA)/Stroke, sponsored by Shirley Ryan AbilityLab. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Stroke by Shirley Ryan AbilityLab — 12 open to participants now, 20 under way, none of them phase 3. Stroke · Shirley Ryan AbilityLab.

Planned enrollment
36th of 55
20 · median 30
Started
2023
with 1 other
No phase
49 of 64
10 open now
Primary completion
2025-12
later than 4 of 19 live
Registered
44th of 64
by date

Among the 64 studies in Stroke by Shirley Ryan AbilityLab, this one is the 36th largest by planned enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2023, is one of 49 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 44th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

12 of the 64 studies in Stroke by Shirley Ryan AbilityLab are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Stroke by Shirley Ryan AbilityLab, or all of them as a file.
02

Study summary

This study is being done to see how errors lead to improvement. Specifically, we are evaluating the errors stroke participants make during an upper extremity exercise program when reaching for a target using their affected arm. Once we understand the participant's reaching errors, we plan to create a customized reaching exercise according to the individual's specific error tendencies which will lead to better performance on movement ability after training.

Read the detailed description

The neuroplasticity of motor re-learning is a key pathway for recovery in neurorehabilitation. One critical challenge to devising treatment plans for motor recovery is the wide variation that exists between individuals, across movement repetitions, and even within movements. Development of a learning model that looks at these factors would better relate diagnoses to treatments, providing personalization and efficiency to therapy. This proposal aims to advance rehabilitation by building a modeling framework that explores the trends and exploits a fundamental learning process - error. Our goal is to preliminarily test the direct effect of this new treatment in preparation for the randomized controlled study to come. Understanding how error leads to better performance will help us program future devices for therapy for optimal outcomes.

We are using research lab equipment at the Shirley Ryan AbilityLab (SRALab) Hospital's Robotics group. The equipment will be used to implement the reaching exercises and measure participant movement. The equipment includes:

  1. Barret b.u.r.t. arm robot with Teneo forearm attachment
  2. LookingGlass virtual reality display system
  3. Garmin Venu Sq fitness tracking wristwatch

Study Outline:

Week 1, Visit 1: Consent, In-Person Screening, and Baseline Evaluations Participants will sign a consent form. Then, they will undergo a screening process to check if they meet all the eligibility requirements. Participants that pass the in-person screening and agree to continue with the study will complete baseline evaluations which will consistent of upper extremity outcome measures, and a preliminary reaching experiment on the b.u.r.t. robotic arm.

Weeks 2-3, Visits 2-7: Treatment Visits In the following two weeks, participants will come to the lab three times a week. They will use the robotic arm, and complete several rounds of reaching exercises while looking in the virtual reality display system. Depending on the treatment visit, participants will either take home a fitness tracker, or be asked to return it.

Week 4, Visit 8: Post-Evaluations About a week after the treatment sessions, participants will return to the lab and complete the same evaluations they completed during visit 1 to see if there is any change.

Weeks 5-8: There will be no lab visits during this time.

Week 9, Visit 9: About 5-6 weeks after the treatment visits, participants will come back for follow-up evaluations. These will be the same outcome measures completed during the baseline and post-evaluation sessions.

03

Conditions studied

  • Stroke
  • Cerebral Vascular Accident (CVA)/Stroke

Browse trials for

Keywords

  • Upper Extremity
  • Rehabilitation
  • Arm
  • Robotics
  • Stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. Chronic stroke (8+ months post stroke event) with primary motor cortex involvement
  3. Hemiparesis
  4. Some degree of both shoulder and elbow movement capability

Exclusion criteria

Exclusion Criteria:

  1. Bilateral paresis
  2. Severe tactile deficits using the Two-Point Discrimination Test (participant must detect\<11mm)
  3. Severe proprioceptive deficits
  4. Severe spasticity (Modified Ashworth >3) preventing movement
  5. Aphasia, cognitive impairment, or affective dysfunction that would influence the ability to perform the experiment
  6. Visual deficits, and hemispatial neglect that would prevent the subjects from seeing the targets.
  7. Inability to provide an
  8. severe current medical problems
  9. diffuse/multiple lesion sites or multiple stroke events
  10. Inability to attain and maintain testing positions
  11. Botox injection to the affected upper extremity within the previous 4 months
  12. Concurrent participation in upper extremity rehabilitation either as part of a research intervention protocol or a prescribed therapy
  13. Participation in previous, similar robotics intervention study
  14. Other neurological issues

None of the following special populations will be included in this research study:

  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners
  • Vulnerable Populations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Group 1

    Other: Error Fields · Other: No Error Fields

  • Other
    Group 2

    Other: Error Fields · Other: No Error Fields

Interventions

  • OtherError Fields

    Participants will complete a reaching experiment using the robotic arm with error fields turned on.

  • OtherNo Error Fields

    Participants will complete a reaching experiment using the robotic arm with error fields turned off.

06

What researchers measure

Primary outcomes

  1. Perpendicular Error

    Time frame: 60-90 minutes

Secondary outcomes

  1. Action Research Arm Test

    Time frame: 5-20 minutes

Other outcomes

  1. Upper Extremity portion of the Fugl-Meyer

    Time frame: 5-20 minutes

  2. Box and Blocks

    Time frame: 5-20 minutes

07

Study locations

3 of 3 sites recruiting
  • Shirley Ryan AbilityLab (Healthy Participants)
    Chicago, Illinois 60611, United States
    Recruiting
  • Shirley Ryan AbilityLab
    Chicago, Illinois 60611, United States
    Recruiting
  • Shirley Ryan AbilityLab
    Chicago, Illinois 60611, United States
    Recruiting
    • Courtney Celian, MS · Contact
    • James Patton, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2025, 33 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 33 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2021
First posted
Jan 6, 2022
StartActual
Mar 1, 2023
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05180786
Responsible party
James Lanphier Patton (Co-Director, Robotics Laboratory, Arms and Hands Lab, Shirley Ryan AbilityLab, Shirley Ryan AbilityLab) — Principal investigator
First posted
Jan 6, 2022
Start date
Mar 1, 2023
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Oct 24, 2024

Study contacts

Courtney Celian
Contact
ccelian@sralab.org
3122381560
Naveed Aghamohammadi
Contact
nagham2@uic.edu
7654215544
James Patton, PhD
principal investigator · Shirley Ryan AbilityLab

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion